当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
BEXSERO, Meningococcal Group B Vaccine
申请企业
GlaxoSmithKline Biologicals
药品名称
BEXSERO, Meningococcal Group B Vaccine
承诺描述
A deferred pediatric study (V72_28) under PREA to evaluate the safety and immunogenicity of BEXSERO in infants 2.5 months through 11 months of age and in children 2 years through 10 years of age for the prevention of invasive group B meningococcal disease.
承诺状态描述
The final report was submitted to FDA on February 12, 2016.